ClinConnect ClinConnect Logo
Search / Trial NCT06316167

Mandatory Hiatoplasty in Sleeve Gastrectomy for Gastro-Esophageal Reflux Disease

Launched by INSTITUTO MEXICANO DEL SEGURO SOCIAL · Mar 11, 2024

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

Incidence Complications Bariatric Surgery Obesity

ClinConnect Summary

This clinical trial is studying the effects of a specific surgical procedure called mandatory hiatoplasty during gastric sleeve surgery, which is used for weight loss. The main goal is to find out how often patients develop gastroesophageal reflux disease (GERD) after this surgery and to compare complication rates, including GERD, among patients. Participants will also fill out a questionnaire after the surgery to share how they feel about their quality of life.

To be eligible for this study, you need to be at least 18 years old and have certain types of obesity. The study is open to all genders, and you must have had gastric sleeve surgery with hiatoplasty at a well-known hospital in Tijuana that specializes in weight loss surgeries. If you're interested in participating, you can expect to share your experiences and help researchers understand the impact of this surgery on patients' lives.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Patients over 18 years of age.
  • Gender indistinct.
  • Overweight, obesity grade I, II, III, super obesity or super-super obesity.
  • Underwent gastric sleeve with hiatoplasty for obesity management at a high volume Tijuana hospital dedicated to bariatric surgery.
  • Exclusion Criteria:
  • Patient records with incomplete information.

About Instituto Mexicano Del Seguro Social

The Instituto Mexicano del Seguro Social (IMSS) is a prominent public institution in Mexico, dedicated to providing comprehensive healthcare services and social security to its members. Established to enhance public health and welfare, IMSS plays a pivotal role in the advancement of medical research and clinical trials aimed at improving patient outcomes. By facilitating innovative studies, IMSS contributes to the development of new therapies and treatments, ensuring that the healthcare system remains at the forefront of scientific progress and responds effectively to the health needs of the population.

Locations

Guadalajara, Jalisco, Mexico

Patients applied

0 patients applied

Trial Officials

José Aldo Guzmán-Barba, MD, PhD

Study Chair

ALO Bariatrics. Gobernador Ibarra 9721, Zona Cacho, 22044, Tijuana, Baja California, México.

Alejandro López-Ortega, MD, PhD

Study Director

ALO Bariatrics. Gobernador Ibarra 9721, Zona Cacho, 22044, Tijuana, Baja California, México.

Helmut Heribert, MD, PhD

Principal Investigator

ALO Bariatrics. Gobernador Ibarra 9721, Zona Cacho, 22044, Tijuana, Baja California, México.

Isaac Esparza Estrada, MD, PhD

Study Chair

ALO Bariatrics. Gobernador Ibarra 9721, Zona Cacho, 22044, Tijuana, Baja California, México.

Sergio Jiram Vazquez-Sánchez, MD

Study Chair

Unidad de Investigación Biomédica 02, Unidad Médica de alta especialidad, Hospital de Especialidades Centro Médico Nacional de Occidente, Instituto Mexicano del Seguro Social, Guadalajara 44329, Mexico

Alejandro González-Ojeda, MD, PhD

Study Chair

Unidad de Investigación Biomédica 02, Unidad Médica de alta especialidad, Hospital de Especialidades Centro Médico Nacional de Occidente, Instituto Mexicano del Seguro Social, Guadalajara 44329, Mexico

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported